Few studies have conducted an international price comparison of generic medicines as it is hard to access comparable data. A 2007 study by Prof. Dr. Steven Simoens examined national pricing policies in some EU countries and related them to generics prices (see Table 1).
International trends in generics: the EU
Generics/Research | Posted 30/08/2010 0 Post your comment
Table 1: Generic medicine pricing policies and generic prices in selected countries in 2005
Country | Generic medicines pricing policy | Average factory gate prices for selected generics, 2005 (Euros) |
Belgium | Generic medicines priced at least 30% lower than the original medicine | 0.206 |
Denmark | Generic medicines priced below the price level of original | 0.104 |
Finland | Free pricing system | 0.220 |
France | Generic medicines priced at least 40% lower than the original medicine | 0.254 |
Germany | Free pricing system | 0.269 |
The Netherlands |
A system of maximum prices based on reference country prices | 0.260 |
Norway | A step-price system is in place that cuts the generic medicine price after a period of time | 0.171 |
Sweden | Regulated generic medicine prices system | 0.123 |
United Kingdom |
Free pricing in a competitive environment | 0.222 |
It is clear that another factor is affecting the price of generics, as the pricing policy does not directly govern the average price of generics. If the data is analysed from the perspective of maturity of the generics market, it can be seen that those countries in which generics have been established over a longer period of time pay less for their medicines (see Table 2).
Table 2: Generic medicine prices compared to regulatory approach and level of development of generic medicine market in 2005
Generic medicine prices and regulatory approach towards generic medicine pricing | |||
Free market pricing | Pricing regulation | ||
Country | Average price level | Country | Average price level |
Finland Germany United Kingdom |
0.237 | Belgium Denmark France The Netherlands Norway Sweden |
0.186 |
Generic medicine prices and level of development of generic medicine market | |||
Developing generic medicine market | Mature generic medicine market | ||
Belgium Finland France Norway |
0.213 | Denmark Germany The Netherlands Sweden United Kingdom |
0.196 |
The international price variation suggests that generic medicine companies do not set prices at a common European level, but adapt their price setting strategy to the regulatory environment surrounding generic medicines in each country. The generic medicine price level was lower in countries that regulate prices and in countries that have a mature generic medicine market.
(see also International comparison of generic medicine prices)
Reference
Simoens S. International comparison of generic medicine prices. Curr Med Res Opin. 2007;23(11):2647–54.
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Generic medications in the Lebanese community: understanding and public perception
Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
Comments (0)
Post your comment